XTL Biopharmaceuticals Ltd.

www.xtlbio.com

High-Tech Company
Public Company

(TASE: XTL), (NASDAQ First North: XTLBY), (NASDAQ CM: XTLB)

TECH VERTICALS

Biopharmaceuticals, Biotechnology, MedTech, Oncology, Psychiatry, Therapeutics

General Data

Sector

Biomed

TECHNOLOGY

The hCDR1 peptide is a novel compound, working via a novel mechanism of action, for the treatment of Systemic Lupus Erythematosus (“SLE”). hCDR1 has completed three clinical trials involving more than 400 patients.

Recombinant Erythr...(Unlock More)...

CONTACT INFO

Personal Contact Information

Blog

Expand / Collapse All

	MANAGEMENT

Key Executive

	BOARD

Board

	FINANCIAL ROUNDS

Round

Date

Stage

Amount

Valuation

PIPE

Mar. 20, 2024

Initial Revenues

$1.5m

N/A

General Info

Angel Company & Title
E-mail
Website
No. of Current Portfolio Companies
Remarks

Business Description

Description
Angel Activity

Investment Data

Managed Capital
Capital Remarks
Capital Available

Preferences

Maximum investments
Minimum investments
Type of Financing
Stage Preferences
Phase Preferences
Industry Preferences

	SECTOR SEGMENTATION (By Number Of Companies)

Current Israeli Clients (#)

	Deals Underwritten (#)

	Deals Legally Advised (#)

	Current Positions

	Previous Positions

	Background

	Education

	Specialties

Last Updated:	Aug 14, 2024
IVC Number:	A1000000008517